Fri. Oct 7th, 2022
uveitis pipeline

DelveInsight’s “Uveitis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Uveitis pipeline landscapes. 

The report comprises Uveitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Uveitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Uveitis pipeline products.     

Uveitis Overview

Uveitis is a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.

Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveals tract.

Some of the key takeaways from the Uveitis Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Santen, EyeGate Pharmaceuticals, Sanofi Aventis, Oculis Pharma,Clearside Biomedical,   etc., are developing therapies for the treatment of Uveitis.
  • Emerging therapies such as Sirolimus, EGP-437, Sarilumab, LME636 (OCS-02), XIPERE formerly known as Suprachoroidal CLS-TA, are expected to have a significant impact on the  Uveitis market in the coming years.

Get an overview of pipeline landscape @ Uveitis Clinical Trials Analysis 

Uveitis Pipeline Therapies along with Key Players:

  • Sirolimus: Santen
  • EGP-437: EyeGate Pharmaceuticals
  • Sarilumab: Sanofi Aventis
  • LME636 (OCS-02): Oculis Pharma
  • XIPERE formerly known as Suprachoroidal CLS-TA: Clearside Biomedical

Scope of Uveitis Pipeline Drug Insight    

  • Coverage: Global 
  • Major Players: Santen, EyeGate Pharmaceuticals, Sanofi Aventis, Oculis Pharma,Clearside Biomedical, and others.
  • Pipeline Therapies: Sirolimus, EGP-437, Sarilumab, LME636 (OCS-02), XIPERE formerly known as Suprachoroidal CLS-TA, and others.

Table of Contents

1 Uveitis Report Introduction
2 Uveitis Executive Summary
3 Uveitis Overview
4 Uveitis- Analytical Perspective In-depth Commercial Assessment
5 Uveitis Pipeline Therapeutics
6 Uveitis Late Stage Products (Phase II/III)
7 Uveitis Mid Stage Products (Phase II)
8 Uveitis Early Stage Products (Phase I)
9 Uveitis Preclinical Stage Products
10 Uveitis Therapeutics Assessment
11 Uveitis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Uveitis Key Companies
14 Uveitis Key Products
15 Uveitis Unmet Needs
16  Uveitis Market Drivers and Barriers
17 Uveitis Future Perspectives and Conclusion
18 Uveitis Analyst Views
19 Appendix
20 About DelveInsight

Get a customized pipeline report @ Uveitis Drugs Pipeline Report  

Related Reports:

Uveitis Market

Uveitis Epidemiology

Latest Reports by DelveInsight

Retinopathy of Prematurity market

Richter Syndrome market

Rotator Cuff Injuries market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Contact Us:

Kritika Rehani

[email protected]





By sthakur

Leave a Reply

Your email address will not be published. Required fields are marked *